On the heels of the US FDA approving dabigatran, the long-awaited alternative to Coumadin (warfarin), comes word that Health Canada has as well. In Canada, dabigatran is known as PRADAX™. Because this is the first alternative to warfarin in Canada, it is big news for the afib community there. Learn more at: Health Canada Approves …
Read More
October 29 is World Stroke Day. You can learn more about steps you can take to prevent a stroke at World Stroke Day, October 29, 2010. Professor Bo Norrving, president of the sponsoring World Stroke Organization, is a member of our StopAfib.org Medical Advisory Board.
Read More
The long-awaited alternative to Coumadin (warfarin) has just been approved by the US FDA. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation for preventing afib-related strokes. The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa …
Read More
An FDA panel today unanimously recommended that the FDA approve dabigatran (Pradaxa) for reducing the risk of afib strokes. FDA approval is expected quickly, making this the first alternative to warfarin approved in the United States, and also the first atrial fibrillation approval for dabigatran. It is approved in over 70 countries for venous thromboembolisms …
Read More
Findings presented at Heart Rhythm 2010 showed that stopping atrial fibrillation—whether through medication, surgery, or in the case of this study, catheter ablation— could potentially prevent the risk of developing Alzheimer’s disease and other dementias and also reduce the risk of stroke and death. Doctors John D. Day, MD, and T. Jared Bunch, MD, at …
Read More
An important session at Heart Rhythm Society 2010 was "Medical Issues After Ablation for Atrial Fibrillation and Flutter." It dealt with what constitutes success following catheter ablation for atrial fibrillation (afib) and atrial flutter, and which is more important, the medical definition or the patient's definition. Which definition is used can have implications for treatment …
Read More
In this video interview, Dr. Nassir Marrouche, Executive Director of the Comprehensive Arrhythmia Research and Management (CARMA) Center at the University of Utah Health System, discusses the findings he recently presented at the Heart Rhythm Society annual meeting in Denver. He discussed the intriguing way they are using MRI (magnetic resonance imaging), to personalize atrial …
Read More
At Heart Rhythm Society 2010, we saw intriguing new research into personalized afib treatment and stroke prevention that was presented by Dr. Nassir Marrouche and Dr. Marcos Daccarett of the Comprehensive Arrhythmia Research and Management (CARMA) Center at the University of Utah Health System. They have developed a way, using MRI (magnetic resonance imaging), to …
Read More
One of the most common questions we get centers around the use of anticoagulant drugs—either the brand drug, Coumadin, or the generic version, warfarin—and whether or not an atrial fibrillation patient should be on them. Anticoagulants decrease stroke risk, but can also increase bleeding risk. How do you sort it all out? It's just as …
Read More
Learn more about World Stroke Day and what atrial fibrillation patients need to know about their stroke risk.
Read More